Northwest Biotherapeutics (NWBO) Operating Expenses (2010 - 2026)

Northwest Biotherapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $11.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 35.58% year-over-year to $11.4 million in Q1 2026; TTM through Mar 2026 was $55.0 million, a 20.92% decrease from a year earlier, with the FY2025 full-year figure at $61.3 million, down 9.72% from the prior year.
• Operating Expenses eased to $11.4 million in Q1 2026 per NWBO's latest filing, from $14.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $21.6 million in Q2 2022 and bottomed at $11.4 million in Q1 2026.
• The 5-year median for Operating Expenses is $15.2 million (2024), against an average of $15.7 million.
• Across the five-year window, Operating Expenses soared 75.86% in 2022 and slumped 36.14% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $18.8 million in 2022, then dropped by 16.98% to $15.6 million in 2023, then rose by 20.16% to $18.7 million in 2024, then declined by 24.31% to $14.2 million in 2025, then fell by 19.62% to $11.4 million in 2026.
• Per Business Quant, the three latest NWBO Operating Expenses figures stand at $11.4 million (Q1 2026), $14.2 million (Q4 2025), and $14.5 million (Q3 2025).